Laparoscopic oophorectomy either with or without hysterectomy for early breast cancer.
OBJECTIVE
The aim of this study was to assess the surgical results, complications and pathological findings of laparoscopic ovarian ablation either with or without hysterectomy in women with early-stage breast cancer (BC).


METHODS
Ninety women in early breast cancer stage who underwent laparoscopic bilateral salpingo-oophorectomy (BSO) either with or without hysterectomy were identified in a retrospective study conducted between January 2000 and December 2006. Tamoxifen antiestrogen therapy was used prior to hysterectomy.


RESULTS
Forty-eight consecutive patients underwent laparoscopic hysterectomy with bilateral salpingo-oophorectomy and 42 with ovarian ablation only. The mean operative time for the laparoscopic hysterectomy and bilateral salpingo-oophorectomy or BSO alone was 82 min and 47.8 min, respectively. Blood loss was minimal in both groups (range: 20-250 ml). The rate of postoperative complications was very low (4.4%). One of all ovaries removed by laparoscopy showed ovarian breast carcinoma metastasis. Histopathologic examination revealed concomitant findings of leiomyoma, adenomyosis or endometrial abnormalities in 64.5% of hysterectomy specimens.


CONCLUSIONS
Our experience with ovarian ablation either with or without hysterectomy confirmed that the use of a minimally invasive technique is feasible. We assume that ovarian ablation and hysterectomy is an appropriate treatment for premenopausal women at risk (BRCA positive) or for patients with concomitant benign uterine pathology, treated with tamoxifen in first-line therapy. Removing the uterus allows women to take only estrogens rather than combination HRT. Further investigation into the indications of disease where laparoscopic ablative surgery is appropriate in the management of early breast cancer is needed.
Kucera
E
E
Department of Obstetrics and Gynecology, Institute of Care for Mother and Child, Prague, Czech Republic.
Holub
Z
Z
Svobodova
G
G
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D019313:BRCA1 Protein / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000601:surgery*; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods*; D008875:Middle Aged; D019060:Minimally Invasive Surgical Procedures; D010052:Ovariectomy / Q000379:methods*; D012189:Retrospective Studies; D013629:Tamoxifen / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D019313:BRCA1 Protein; D013629:Tamoxifen